An exploratory analysis of co-mutations in a clinical trial cohort showed a trend toward a higher response rate in STK11-co-mutated tumours (64 vs. 33% in WT), while, conversely, KEAP1 and TP53 co-mutations were not predictive of response [84]. Here, KEAP1 is linked to neoplasm.